Uses and safety profile of ciclosporin in ophthalmology

Bibliography

• De Smet MD, Nussenblat RB. Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin 1993;33(4):31-45
   Google Scholar
• Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977;32(6):1017-25
   PubMed Web of Science ®Google Scholar
• Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14(6):290-5
   PubMedGoogle Scholar
• Nussenblat RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986;31(3):159-69
   PubMed Web of Science ®Google Scholar
• Foulks G. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 2006;46(4):105-22
   PubMedGoogle Scholar
• Nussenblat RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96(3):275-82
   PubMed Web of Science ®Google Scholar
• Coster DJ, Shepherd WF, Fook TC, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet 1979;2(8144):688-9
   PubMed Web of Science ®Google Scholar
• Hunter PA, Wilhelmus KR, Rice NS, et al. Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol 1981;45(1):173-7
   PubMed Web of Science ®Google Scholar
• Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract 1990;20(3):583-613
   PubMed Web of Science ®Google Scholar
• Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005;89(10):1363-7
   PubMed Web of Science ®Google Scholar
• Bettelman E, Pleyer U. Immunomodulatory therapy in ophthalmology – is there a place for topical application? Ophthalmologica 2004;218(6):359-67
   PubMed Web of Science ®Google Scholar
• Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye. Cornea 1990;9(3):196-9
   PubMed Web of Science ®Google Scholar
• Kanai A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc 1989;21(1):3150-2
   PubMed Web of Science ®Google Scholar
• Tilney N, Strom TB, Kupiec-Weglinski JW. Pharmacologic and immunologic agonists and antagonists of cyclosporine. Transplant Proc 1988;20(3):13-22
   PubMedGoogle Scholar
• Golet OJ, Revillon Y, Gubler MC, et al. Renal function and histomorphology after long-term intravenous administration of cyclosporine for small bowel transplantation in pediatric patients. Transplant Proc 1994;26(3):1428
   PubMed Web of Science ®Google Scholar
• Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep 2001;3(5):434-9
   PubMedGoogle Scholar
• Feutren G. The optimal use of cyclosporin A in autoimmune disease. J Autoimmune 1992;Suppl A:183-95
   PubMedGoogle Scholar
• Kassianides C, Nussenblatt RB, Palestine AG, et al. Liver injury from cyclosporine A. Dig Dis Sci 1990;35(6):693-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study. Ann Neurol 1988;23(1):56-63
   PubMed Web of Science ®Google Scholar
• Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol 1994;72(4):438-42
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998;105(9):1715-20
   PubMed Web of Science ®Google Scholar
• Bar OB, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;27:71(8):1051-5
   Google Scholar
• Bung P, Molitor DJ. Pregnancy and postpartum after kidney transplantation and cyclosporin therapy – review of the literature adding a new case. Perinat Med 1991;19(5):397-401
   PubMedGoogle Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998;82(7):737-42
   PubMed Web of Science ®Google Scholar
• Chueng MK, Rosenbaum E. Immunosuppressive therapy for uveitis. In: Textbook of ocular pharmacology. Zimmerman TJ (Ed.), Lippencott–Raven publishers, New York; pp. 95-119
   Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137(2):337-42
   PubMed Web of Science ®Google Scholar
• Gilbard JP. The scientific context and basis of the pharmacologic management of dry eyes. Ophthalmol Clin North Am 2005;18(4):475-84
   PubMedGoogle Scholar
• Williams DL. A comparative approach to topical cyclosporine therapy. Eye 1997;11(4):453-64
   PubMed Web of Science ®Google Scholar
• Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989;107(8):1210-16
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993;12(4):315-23
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107(4):631-9
   PubMed Web of Science ®Google Scholar
• Hom MM. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens – intolerant patients. Eye Contact Lens 2006;32(2):109-11
   PubMedGoogle Scholar
• Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32(5):772-8
   PubMed Web of Science ®Google Scholar
• Bonini S, Coassin M, Aronni S, et al. Vernal keratoconjunctivitis. Eye 2004;18(4):345-51
   PubMed Web of Science ®Google Scholar
• Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal conjunctivitis. Am J Ophthalmol 1990;110(6):641-5
   PubMed Web of Science ®Google Scholar
• Bleik JH, Tabbara KF. Topical cyclosporine in vernal conjunctivitis. Ophthalmology 1991;98(11):1679-84
   PubMed Web of Science ®Google Scholar
• Cetinkaya A, Akoya YA, Dursun D, et al. Topical cyclosporine in the management of shield ulcers. Cornea 2004;23(2):194-200
   PubMed Web of Science ®Google Scholar
• Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eye drops in vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641-5
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111(3):476-82
   PubMed Web of Science ®Google Scholar
• Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical cyclosporine A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90(4):461-4
   PubMed Web of Science ®Google Scholar
• Watson SL, Hollingsworth J, Tullo AB. Confocal microscopy of Thygeson's Superficial punctuate keratopathy. Cornea 2003;22(4):294-9
   PubMed Web of Science ®Google Scholar
• Reinhard T, Sundmacher R. Topical cyclosporin A in Thygeson's superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 1999;237(2):109-12
   PubMed Web of Science ®Google Scholar
• Belin MW, Bouchard CS, Frantz S, et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96(8):1144-50
   PubMed Web of Science ®Google Scholar
• Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns 2004. Cornea 2006;25(3):286-90
   PubMed Web of Science ®Google Scholar
• Oh C, Apel AJ, Saville BA, et al. Local efficiency of cyclosporine in corneal transplant therapy. Curr Eye Res 1994;13:337-43
   PubMed Web of Science ®Google Scholar
• Bouchard CS, Cavanagh HD. The high risk keratoplasty patient-quo vadis? Cornea 1994;13(1):1-3
   PubMed Web of Science ®Google Scholar
• Inoue K, Amano S, Kimura C, et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 2000;44(3):302-5
   PubMed Web of Science ®Google Scholar
• Kervick GN, Pflufelder SC, Haimovici R, et al. Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology 1992;99(1):80-8
   PubMed Web of Science ®Google Scholar
• Chen J, Xie H, Wang Z, et al. Mooren's ulcer in China: a study of clinical characteristics and treatment. Br J Ophthalmol 2000;84(11):1244-9
   PubMed Web of Science ®Google Scholar
• Akpek EK, Illhan-Sarac O, Green WR. Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva. Arch Ophthalmol 2003;121(9):1333-5
   PubMed Web of Science ®Google Scholar
• Perry HD, Doshi-Carnevale S, Donnenfled ED. Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology 2003;110(8):1578-81
   PubMed Web of Science ®Google Scholar
• Neumann R, Dutt CJ, Foster CS. Immunohistopathologic features and therapy of conjunctival lichen planus. Am J Ophthalmol 1993;115(4):494-500
   PubMed Web of Science ®Google Scholar
• Lelli GJ, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006;25(6):635-8
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112(8):1472-7
   PubMed Web of Science ®Google Scholar
• Kanski JJ. Uveitis. In: Clinical ophthalmology. A systemic approach. (Volume 6). Kanski JJ (Ed.), Butterworth Heinmann Elsevier publishers, London 2007; pp. 441-504
   Google Scholar
• Vries JD, Baarsma GS, Zaal MJ, et al. Cyclosporin in treatment of idiopathic uveitis. Br J Ophthalmol 1990;74:344-9
   PubMed Web of Science ®Google Scholar
• Caspi RR, Roberg FG, Chan CC, et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988;140(5):1490-5
   PubMed Web of Science ®Google Scholar
• Kulkarni P. Uveitis and immunosuppressive drugs. J Ocul Pharmacol 2001;17(2):181-7
   Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double masked study of cyclosporine compared to prednisolone in the treatment of endogenos uveitis. Am J Ophthalmol 1991;112(2):138-45
   PubMed Web of Science ®Google Scholar
• Dios Castro E, Herreras Cantalapiedra JM, Calonge Cano M, et al. Ocular sarcoidosis. Retrospective study of 18 cases. Arch Soc Esp Oftalmol 2002;77(6):301-8
   PubMedGoogle Scholar
• Evereklioglu C. Current concepts in the etiology and treatment of Bechet disease. Surv Ophthalmol 2005;50(4):297-350
   PubMed Web of Science ®Google Scholar
• Damico FM, Kiss S, Young LH. Vogt-koyanagi-Harada disease. Semin Ophthalmol 2005;20(3):183-90
   PubMedGoogle Scholar
• Damico FM, Kiss S, Young LH. Sympathetic ophthalmia. Semin Ophthalmol 2005;20(3):191-7
   PubMedGoogle Scholar
• Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol 2005;50(6):519-41
   PubMed Web of Science ®Google Scholar
• Bonfioli AA, Damico FM, Curi AL, et al. Intermediate uveitis. Semin Ophthalmol 2005;20(3):147-54
   PubMedGoogle Scholar
• Kanski JJ. Episclera and sclera. In: Clinical ophthalmology. A systemic approach (Volume 6). Kanski JJ (ed.), Butterworth Heinmann Elsevier publishers, London 2007; pp. 323-34
   Google Scholar
• Hakin KN, Ham S, Lightman SL. Use of cyclosporine in the management of steroid dependent non necrotizing scleritis. Br J Ophthalmol 1991;75(6):340-1
   PubMed Web of Science ®Google Scholar
• Wakefield D, Mccluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol 1989;73(9):743-6
   PubMed Web of Science ®Google Scholar
• Mccarthy JM, Dubord PJ, Chalmers A, et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol 1992;19(9):1358-61
   PubMed Web of Science ®Google Scholar
• Poon AC, Forbes JE, Dart JK, et al. Systemic cyclosporine in high risk penetrating keratoplasties: a case control study. Br J Ophthalmol 2001;85(12):1464-9
   PubMed Web of Science ®Google Scholar
• Bell TA, Easty DL, Mccullagh KG. A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits. Br J Ophthalmol 1982;66(5):303-8
   PubMed Web of Science ®Google Scholar
• Hill JC. The use of cyclosporine in high risk keratoplasty. Am J Ophthalmol 1989;107(5):506-10
   PubMed Web of Science ®Google Scholar
• Hill JC. Systemic cyclosporine in high risk keratoplasty: short versus long term therapy. Ophthalmology 1994;101(1):128-33
   PubMed Web of Science ®Google Scholar
• Robert PY, Delbosc B, Preux PM. Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases. J Fr Ophthalmol 1997;20(7):507-14
   PubMed Web of Science ®Google Scholar
• Rumelt S, Bersudsky V, Blum-Hareuveni T, et al. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 2002;86(9):988-92
   PubMed Web of Science ®Google Scholar
• Young AL, Rao SK, Cheng LL, et al. Combined intravenous pulse methylprednisolone and oral cyclosporin A in treatment of corneal graft rejection: 5 year experience. Eye 2002;16(3):304-8
   PubMed Web of Science ®Google Scholar
• Bielory L, Frohman LP. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991;98(11):1732-6
   PubMed Web of Science ®Google Scholar
• Meyer PA. Avoiding surgery for thyroid eye disease. Eye 2006;20(10):1171-7
   PubMed Web of Science ®Google Scholar
• Alonso A, Bignone ML, Brunzini M, et al. Ocular autoimmune pemphigoid and cyclosporin A. Allergol Immunopathol 2006;34(3):113-15
   PubMedGoogle Scholar
• Daniell MD, Dart JC, Lightman S. Use of cyclosporine in the treatment of steroid resistant post keratoplasty atopic sclerokeratitis. Br J Ophthalmol 2001;85(1):91-2
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998;6(2):101-9
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106(4):723-8
   PubMed Web of Science ®Google Scholar
• Kaplan-Messas A, Barkana Y, Avni I. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003;11(2):131-9
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998;352(9121):35-6
   PubMed Web of Science ®Google Scholar
• Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106(2):370-4
   PubMed Web of Science ®Google Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short term safety. Ophthalmology 2004;111(5):960-5
   PubMed Web of Science ®Google Scholar
• Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolayngol 1965;69:279-93
   Google Scholar
• Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic non infectious uveitis. Ophthalmology 2001;108(6):1134-9
   PubMed Web of Science ®Google Scholar
• Shah SS, Lowder CY, Schmitt MA, et al. Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99(9):1419-23
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plakova J, et al. Cyclosporine and tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123(5):634-41
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick A, et al. Long term efficacy and tolerance of tacrolimus for treatment of uveitis. Ophthalmology 2007;114(5):1000-6
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Casely EM, Raj D. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89(6):666-9
   PubMed Web of Science ®Google Scholar
• Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110(5):1061-5
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, et al. Long term follow up of patients treated with short term high dose chlorambucil for sight threatening ocular inflammation. Ophthalmology 2002;109(2):370-7
   PubMed Web of Science ®Google Scholar
• Reis A, Reinhard T, Voiculescu A. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999;83(11):1268-71
   PubMed Web of Science ®Google Scholar
• Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001;239(5):367-72
   PubMed Web of Science ®Google Scholar
• Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high risk keratoplasty: a retrospective study. Transplantation 2005;79(8):964-8
   PubMed Web of Science ®Google Scholar
• Birnbaum F, Reis A, Bohringer D, et al. An open prospective pilot study on the use of rapamycin after penetrating high risk keratoplasty. Transplantation 2006;81(5):767-72
   PubMed Web of Science ®Google Scholar
• Mayer K, Rienhard T, Reis A, et al. FK506 ointment 0.1% – a new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monatsbl Augenheikd 2001;218(11):733-6
   PubMed Web of Science ®Google Scholar
• Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24(4):417-20
   PubMed Web of Science ®Google Scholar